BioArctic AB
B9A
Company Profile
Business description
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
Contact
Warfvinges vag 35
StockholmSE-112 51
SWET: +46 86956930
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
131
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Our view of the proposed merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.20 | 123.30 | -1.31% |
| CAC 40 | 8,197.77 | 196.55 | -2.34% |
| DAX 40 | 23,878.38 | 759.62 | -3.08% |
| Dow JONES (US) | 48,904.78 | 73.14 | -0.15% |
| FTSE 100 | 10,535.10 | 245.01 | -2.27% |
| HKSE | 25,768.08 | 612.94 | -2.32% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 56,279.05 | 2,474.34 | -4.21% |
| NZX 50 Index | 13,620.21 | 50.50 | -0.37% |
| S&P 500 | 6,881.62 | 2.74 | 0.04% |
| S&P/ASX 200 | 9,077.30 | 104.40 | -1.14% |
| SSE Composite Index | 4,122.68 | 59.92 | -1.43% |